EBITDA Margin % is calculated as EBITDA divided by its Revenue. SciBase Holding AB's EBITDA for the
three
months ended in Mar. 2026 was kr-24.20 Mil. SciBase Holding AB's Revenue for the
three
months ended in Mar. 2026 was kr14.28 Mil. Therefore, SciBase Holding AB's EBITDA margin for the quarter that ended in Mar. 2026 was -169.49%.
SciBase Holding AB (OSTO:SCIB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SciBase Holding AB EBITDA Margin % Related Terms
SciBase Holding AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SciBase Holding AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SCIB vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, SciBase Holding AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciBase Holding AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SciBase Holding AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciBase Holding AB (OSTO:SCIB) has a EBITDA Margin % of -169.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SciBase Holding AB and its competitors. According to the industry distribution chart, SciBase Holding AB ranks #706 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 86.6%.
Is SciBase Holding AB's EBITDA Margin % too high?
SciBase Holding AB's current EBITDA Margin % is -169.49%. Based on the distribution chart, SciBase Holding AB ranks #706 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SciBase Holding AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciBase Holding AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SciBase Holding AB ranks #706 out of 815 companies for EBITDA Margin %. This places SciBase Holding AB in the lower half of its industry. The industry median EBITDA Margin % is 7.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SciBase Holding AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciBase Holding AB's current EBITDA Margin % is -169.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciBase Holding AB stock overvalued right now?
Based on GuruFocus' analysis, SciBase Holding AB (OSTO:SCIB) is currently considered Significantly Overvalued. The stock's GF Value™ is kr21.74, compared to a current price of kr33.80 — trading 55.5% above its estimated fair value. The current EBITDA Margin % is -169.49%. SciBase Holding AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SciBase Holding AB (OSTO:SCIB), the current EBITDA Margin % is -169.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?
Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued.
The current stock price of kr33.80 is trading 55.5% above its estimated GF Value™ of kr21.74.
GuruFocus considers SciBase Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:SCIB:
EBITDA Margin %: -169.49%
GF Value™: kr21.74 vs. price of kr33.80 (55.5% above fair value)
No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
50GF Score
Get the complete analysis for OSTO:SCIB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SCIB has been successfully added to your 
